“Epirubicin and Docetaxel As Neoadjuvant Treatment of Hormone Receptor Positive, HER-2 Negative Breast Cancer: Results from Two Successive Phase II Studies”. Radiology and Oncology 47, no. 1 (April 2, 2013). Accessed October 25, 2026. https://radioloncol.com/index.php/ro/article/view/728.